Trial Profile
A Phase Ib, Multi-center, Open-label, Dose-escalation Study of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 Administered Orally in Patients With Myelofibrosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PIM 447 (Primary) ; Ribociclib (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Jan 2021 Status changed from active, no longer recruiting to completed.
- 03 Nov 2020 Planned End Date changed from 14 Oct 2020 to 9 Nov 2020.
- 03 Nov 2020 Planned primary completion date changed from 14 Oct 2020 to 9 Nov 2020.